Clinical Trial

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer. Pembrolizumab is allowed in both arms after approval for TNBC 2022.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-04-02; most recent amendment 2025-09-05.
Status change: Recruiting → Active, Not Recruiting 2025-09-05
Trial Details
NCT Number NCT04335669
Lead Sponsor Lund University Hospital
Collaborators: Swedish Breast Cancer Group, Danish Breast Cancer Cooperative Group
Conditions Breast Cancer, Triple Negative Breast Neoplasms
Enrollment 325 participants
Start Date 2019-12-20
Primary Completion 2035-09 (estimated)
Study Completion 2035-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-12